ArticleNature nanotechnology2023
Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma.
Article in Nature nanotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.
- Analysis of multi-drug cancer nanomedicine.Nature nanotechnology · 2025Pooled it
- Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs.Angewandte Chemie (International ed. in English) · 2026Article
- Hydrolytically Degradable Polyethylene Glycol Bottlebrush Polymers Address the Stability-Clearance Trade-Off for Drug Delivery.Polymer science & technology (Washington, D.C.) · 2026Article
- Targeting the immune-metabolic axis reverses orthodontics-induced systemic pathology.Signal transduction and targeted therapy · 2026Article
- An In Situ HAdvanced materials (Deerfield Beach, Fla.) · 2026Article
- Spatiotemporal activation of unfolded protein response by combined sonodynamic therapy and proteasome inhibition with bortezomib-conjugated TiN nanoparticles.Bioactive materials · 2026Article
- HDAC INHIBITION SENSITIZES PANCREATIC TUMORS TO DNA DAMAGE BY GLOBAL REDISTRIBUTION OF THE TRANSCRIPTIONAL MACHINERY.bioRxiv : the preprint server for biology · 2026Article
- Oral Rhizoma Coptis Alkaloids Nanoparticle for Treating Diabetes Through Regulating PI3K/Akt Pathways.Pharmaceutics · 2026Article
- Effective combinatorial antifungal therapy using a host defense peptide mimic that self-assembles into delivery micelles.Nature biotechnology · 2026Article
- Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer.ACS nano · 2025Article
- Polypept(o)ide Based Biodegradable Cylindrical Polymer Brushes: Controlling Size, Shape, Surface Functionality, and Stability.ACS applied materials & interfaces · 2025Article
- SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations.Bioconjugate chemistry · 2025Article
- Nano-oncology revisited: Insights on precise therapeutic advances and challenges in tumor.Fundamental research · 2025Review
- Ultrasound-activated carrier-free nanoprodrugs enhanced universality and efficiency of solid tumor-targeting chemotherapy.Bioactive materials · 2025Article
- Viscoelastic Response of Double Hydrophilic Block Copolymers for Drug Delivery Applications.Polymers · 2025Article
- Polypept(o)ide-Based Core-Shell Bottlebrush Polymers: A Versatile Platform for Drug Encapsulation.Macromolecular bioscience · 2025Article
- Molecular Structure of Foldable Bottlebrush Polymers in Melts.Macromolecules · 2025Article
- Femtosecond laser-ablative aqueous synthesis of multi-drug antiviral nanoparticles.Nanomedicine (London, England) · 2025Article
- A Library of Polyphenol-Amino Acid Condensates for High-Throughput Continuous Flow Production of Nanomedicines with Ultra-High Drug Loading.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Article
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Cancer therapies often have narrow therapeutic indexes and involve potentially suboptimal combinations due to the dissimilar physical properties of drug molecules. Nanomedicine platforms could address these challenges, but it remains unclear whether synergistic free-drug ratios translate to nanocarriers and whether nanocarriers with multiple drugs outperform mixtures of single-drug nanocarriers at the same dose. Here we report a bottlebrush prodrug (BPD) platform designed to answer these questions in the context of multiple myeloma therapy. We show that proteasome inhibitor (bortezomib)-based BPD monotherapy slows tumour progression in vivo and that mixtures of bortezomib, pomalidomide and dexamethasone BPDs exhibit in vitro synergistic, additive or antagonistic patterns distinct from their corresponding free-drug counterparts. BPDs carrying a statistical mixture of three drugs in a synergistic ratio outperform the free-drug combination at the same ratio as well as a mixture of single-drug BPDs in the same ratio. Our results address unanswered questions in the field of nanomedicine, offering design principles for combination nanomedicines and strategies for improving current front-line monotherapies and combination therapies for multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.